Novavax vaccine recommended for approval for EU teenagers

A positive recommendation from the EU committee CHMP concerning the use of the Novavax vaccine in teenagers has turned Novavax’s stock fortunes upside down after months of losses.
by marketwire, translated by catherine brett

Shares in US-based vaccine producer Novovax increased in value by 13.9% on Thursday in US trading after the Committee for Medicinal Products for Human Use, the CHMP, recommended the vaccine be used in children aged 12-17.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading